We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.
For more information visit our privacy policy.Licence Agreement between TopRidge Pharma Limited and AstraZeneca Pharma India Limited for IMDURLicence Agreement • January 22nd, 2018 • England
Contract Type FiledJanuary 22nd, 2018 JurisdictionTHIS LICENSE AGREEMENT (hereinafter called "Agreement") is effective as of this _____ day of ___________ 2018 (hereinafter called "Effective Date"), between TopRidge Pharma Limited (formerly named as EVEREST FUTURE LIMITED), a corporation organised and existing under the law of Hong Kong (Registration No:2333670) and having its principal place of business at Unit A,11/F,Chung Pont Commercial Building,300 Hennessy Road, Wanchai, Hong Kong (hereinafter called "TP") of the one part, and AstraZeneca Pharma India Limited, a company incorporated in India under the Companies Act, 1956 (CIN No: L24231KA1979PLC003563) with its registered office address at Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore – 560045 (hereinafter called " AstraZeneca” , or “AZPIL”).